BACKGROUND: Pro-inflammatory monocytes/macrophages may contribute to increased atherosclerosis in human immunodeficiency virus (HIV)-infected patients. We investigate--to our knowledge, for the first time--sCD163 and other markers of monocyte activation in relationship to atherosclerotic plaque in HIV-infected patients. METHODS: One hundred two HIV-infected and 41 HIV-seronegative men with equivalent cardiovascular risk factors and without history of coronary artery disease were prospectively recruited and underwent computed tomography coronary angiography. RESULTS: sCD163 levels and presence of plaque were significantly higher among antiretroviral-treated subjects with undetectable HIV RNA levels, compared with seronegative controls (1172 ± 646 vs. 883 ± 561 ng/mL [P = .02] for sCD163 and 61% vs. 39% [P = .03] for presence of plaque). After adjusting for age, race, lipids, blood pressure, glucose, smoking, sCD14, and HIV infection, sCD163 remained independently associated with noncalcified plaque (P = .008). Among HIV-infected patients, sCD163 was associated with coronary segments with noncalcified plaque (r = 0.21; P = .04), but not with calcium score. In contrast, markers of generalized inflammation, including C-reactive protein level, and D-dimer were not associated with sCD163 or plaque among HIV-infected patients. CONCLUSIONS: sCD163, a monocyte/macrophage activation marker, is increased in association with noncalcified coronary plaque in men with chronic HIV infection and low or undetectable viremia. These data suggest a potentially important role of chronic monocyte/macrophage activation in the development of noncalcified vulnerable plaque. CLINICAL TRIAL REGISTRATION: NCT00455793.
BACKGROUND: Pro-inflammatory monocytes/macrophages may contribute to increased atherosclerosis in human immunodeficiency virus (HIV)-infectedpatients. We investigate--to our knowledge, for the first time--sCD163 and other markers of monocyte activation in relationship to atherosclerotic plaque in HIV-infectedpatients. METHODS: One hundred two HIV-infected and 41 HIV-seronegative men with equivalent cardiovascular risk factors and without history of coronary artery disease were prospectively recruited and underwent computed tomography coronary angiography. RESULTS: sCD163 levels and presence of plaque were significantly higher among antiretroviral-treated subjects with undetectable HIV RNA levels, compared with seronegative controls (1172 ± 646 vs. 883 ± 561 ng/mL [P = .02] for sCD163 and 61% vs. 39% [P = .03] for presence of plaque). After adjusting for age, race, lipids, blood pressure, glucose, smoking, sCD14, and HIV infection, sCD163 remained independently associated with noncalcified plaque (P = .008). Among HIV-infectedpatients, sCD163 was associated with coronary segments with noncalcified plaque (r = 0.21; P = .04), but not with calcium score. In contrast, markers of generalized inflammation, including C-reactive protein level, and D-dimer were not associated with sCD163 or plaque among HIV-infectedpatients. CONCLUSIONS: sCD163, a monocyte/macrophage activation marker, is increased in association with noncalcified coronary plaque in men with chronic HIV infection and low or undetectable viremia. These data suggest a potentially important role of chronic monocyte/macrophage activation in the development of noncalcified vulnerable plaque. CLINICAL TRIAL REGISTRATION: NCT00455793.
Authors: Priscilla Y Hsue; Peter W Hunt; Elizabeth Sinclair; Barry Bredt; Arlana Franklin; Maudi Killian; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; David D Waters; Steven G Deeks Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Lehn K Weaver; Katharine A Hintz-Goldstein; Patricia A Pioli; Kathleen Wardwell; Nilofer Qureshi; Stefanie N Vogel; Paul M Guyre Journal: J Leukoc Biol Date: 2006-07 Impact factor: 4.962
Authors: Tricia H Burdo; Margaret R Lentz; Patrick Autissier; Anitha Krishnan; Elkan Halpern; Scott Letendre; Eric S Rosenberg; Ronald J Ellis; Kenneth C Williams Journal: J Infect Dis Date: 2011-07-01 Impact factor: 5.226
Authors: Christian A Schaer; Gabriele Schoedon; Alexander Imhof; Michael O Kurrer; Dominik J Schaer Journal: Circ Res Date: 2006-09-28 Impact factor: 17.367
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Rebeccah A McKibben; Joseph B Margolick; Steven Grinspoon; Xiuhong Li; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Richard T George; Lisa P Jacobson; Matthew Budoff; Russell P Tracy; Todd T Brown; Wendy S Post Journal: J Infect Dis Date: 2014-10-30 Impact factor: 5.226
Authors: Florencia Pereyra; Janet Lo; Virginia A Triant; Jeffrey Wei; Maria J Buzon; Kathleen V Fitch; Janice Hwang; Jennifer H Campbell; Tricia H Burdo; Kenneth C Williams; Suhny Abbara; Steven K Grinspoon Journal: AIDS Date: 2012-11-28 Impact factor: 4.177
Authors: Markella V Zanni; Suhny Abbara; Janet Lo; Bryan Wai; David Hark; Eleni Marmarelis; Steven K Grinspoon Journal: AIDS Date: 2013-05-15 Impact factor: 4.177
Authors: Joshua A Walker; Megan L Sulciner; Katherine D Nowicki; Andrew D Miller; Tricia H Burdo; Kenneth C Williams Journal: AIDS Res Hum Retroviruses Date: 2014-03-11 Impact factor: 2.205
Authors: Alison G Abraham; Annie Darilay; Heather McKay; Joseph B Margolick; Michelle M Estrella; Frank J Palella; Robert Bolan; Charles R Rinaldo; Lisa P Jacobson Journal: J Infect Dis Date: 2015-03-11 Impact factor: 5.226